EP Wealth Advisors LLC Buys Shares of 11,500 ProQR Therapeutics (NASDAQ:PRQR)

EP Wealth Advisors LLC acquired a new position in shares of ProQR Therapeutics (NASDAQ:PRQR) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,500 shares of the biopharmaceutical company’s stock, valued at approximately $26,000.

Several other large investors have also made changes to their positions in PRQR. RFG Advisory LLC purchased a new position in ProQR Therapeutics in the first quarter valued at about $73,000. BNP Paribas Financial Markets raised its position in ProQR Therapeutics by 120.1% in the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 19,100 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in ProQR Therapeutics in the first quarter valued at about $56,000. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Stock Performance

Shares of PRQR stock opened at $1.88 on Friday. The business has a 50 day moving average of $1.79 and a two-hundred day moving average of $2.00. ProQR Therapeutics has a 52 week low of $1.11 and a 52 week high of $3.29.

ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. The company had revenue of $4.83 million during the quarter, compared to the consensus estimate of $3.31 million. ProQR Therapeutics had a negative return on equity of 61.58% and a negative net margin of 260.75%. On average, research analysts forecast that ProQR Therapeutics will post -0.37 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on PRQR. Citigroup raised their price objective on ProQR Therapeutics from $1.80 to $2.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. StockNews.com raised ProQR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 29th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of ProQR Therapeutics in a research report on Friday, May 10th. Finally, Chardan Capital reiterated a “buy” rating and issued a $2.50 price target on shares of ProQR Therapeutics in a research note on Friday, May 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $3.38.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).